In addition, as discussed earlier, there are several biomarkers that can predict prognosis or treatment response in CRC such as MSI-H/dMMR (susceptibility to immune checkpoint inhibitors) as well as KRAS/BRAF (anti-EGFR resistance). The gene discussed is KRAS; the disease is colorectal carcinoma.